Futura Medical plc (LSE:FUM) put itself up for sale in September 2026, and the first deadline in that process is due on 2 October. This article explains why the sexual health products company launched a formal sale process, what has happened since, and what its interim results show about its position going into the deadline.
A topical gel specialist
Futura Medical, quoted on AIM since 2003, develops sexual health products based on topically delivered gel formulations. Its lead product is Eroxon, a gel for erectile dysfunction, which is sold in the US through partners and earns royalties. Its pipeline includes Eroxon Intense, which has received EU market clearance and for which the company anticipates FDA clearance in the fourth quarter of 2026, and WSD4000, a product for female sexual health. The company says WSD4000 showed statistical superiority over placebo across key measures in a controlled study.
Fundraise and formal sale process
On 3 September 2026, Futura announced a conditional fundraise of about £1.6 million through a placing and subscription at 0.2p per share, plus a retail offer of up to £150,000. At the same time, it launched a formal sale process under the Takeover Code, alongside a wider M&A process, with Present Value Ltd as specialist adviser. The company said it believed its "current market valuation does not adequately reflect the strategic value" of its portfolio, particularly WSD4000, for which it estimated potential peak sales above US$400 million a year. Non-binding proposals were requested by 2 October 2026. The company said the proceeds would extend its cash runway into February 2027.
Shareholders approved all resolutions at a general meeting on 23 September, each with about 97% support, and the new shares were expected to be admitted on or around 25 September, taking the total in issue to 1,482,327,755. A same-day correction confirmed that 100,000,000 retail offer shares were included, the retail offer having been oversubscribed. Separately, on 10 September, Futura said non-executive director Roy Davis would step down on 20 October 2026, leaving a four-member board, and that no replacement would be appointed at present.
What the interim results showed
Interim results for the six months to 30 June 2026, published on 1 September, explain the urgency. Revenue was £1.62 million, compared with £1.00 million a year earlier, but £1.40 million of this came from a settlement with Haleon, whose commercial relationship with Futura has concluded. Underlying revenue was only about £0.21 million, mainly US Eroxon royalties. The operating loss narrowed to £1.20 million from £6.72 million, the earlier figure including £4.05 million of one-off costs, and administrative expenses fell 17% to £2.19 million.
Cash was £1.24 million at 30 June and £1.06 million at 31 July 2026. Before the fundraise, the company said it had sufficient cash only until about October 2026 and flagged material uncertainty over going concern. It has since appointed Market Performance Group as a new US partner for Eroxon and reported advanced negotiations in China, Korea, Taiwan and Turkey.
Risks and points to watch
A formal sale process does not ensure any offer, and proposals, if received, may be non-binding or conditional. Underlying revenue is small, so the Business depends on partners and new launches. The February 2027 runway is limited, meaning further funding may be needed if no transaction materialises. Regulatory timing for Eroxon Intense and progress with WSD4000 could influence any valuation of the business.
Conclusion
Futura Medical reaches a key point in its sale process because non-binding proposals were requested by 2 October 2026, following a fundraise that extended its runway into February 2027. The interim figures show limited underlying revenue and tight cash, which helps explain why the board is testing the value of its portfolio through a sale or other transaction.






Please wait processing your request...